Dbv Technologies S A Revenue Growth Rates (DBVT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Dbv Technologies S a   (NASDAQ: DBVT)
 

DBVT's Revenue Growth by Quarter and Year

Dbv Technologies S A 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/DBVT/growth
https://api.csimarket.com/api/v1/companies/DBVT/fundamentals
https://api.csimarket.com/api/v1/companies/DBVT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
DBVT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1.60
2nd Quarter June 0.70
1st Quarter March 0.90
FY 3.20

DBVTs Annual Revenue
Dbv Technologies S A 's Revenue in the fiscal year 2025 $ 5.64 millions
Dbv Technologies S A 's Revenue in the fiscal year 2024 $ 4.15 millions
Dbv Technologies S A 's Revenue in the fiscal year 2023 $ 15.73 millions
Dbv Technologies S A 's Revenue in the fiscal year 2022 $ 4.84 millions
Dbv Technologies S A 's Revenue in the fiscal year 2021 $ 5.71 millions




DBVT Revenue third quarter 2026 Y/Y Growth Comment
Dbv Technologies S A reported fall in Revenue in the third quarter 2026 by -42.24% to $ 1.60 millions, from the same quarter in 2025.
Despite modest results in the third quarter 2026, contraction in Dbv Technologies S A 's Revenue appears to be smaller than Company's recent average decline.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 31 other companies have achieved higher Revenue growth. While Dbv Technologies S A ' s Revenue drop of -42.24% ranks overall at the positon no. 1555 in the third quarter 2026.


DBVT Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -42.24 %
2nd Quarter June -53.33 %
1st Quarter March 12.5 %
FY   -

Financial Statements
Dbv Technologies S A 's third quarter 2026 Revenue $ 1.60 millions DBVT's Income Statement
Dbv Technologies S A 's third quarter 2025 Revenue $ 2.77 millions Quarterly DBVT's Income Statement


DBVT Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 128.57 %
2nd Quarter June -22.22 %
1st Quarter March 40.63 %
FY (Year on Year)   -


Back to DBVT Growth rate Comparisons >> Back to DBVT Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #32
Healthcare Sector #255
Overall #1555

Revenue Y/Y Growth Statistics
High Average Low
63.18 % -2870.49 % -22854.92 %
(Mar 31 2026)   (Dec 31 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #32
Healthcare Sector #255
Overall #1555
Revenue Y/Y Growth Statistics
High Average Low
63.18 % -2870.49 % -22854.92 %
(Mar 31 2026)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Dbv Technologies S A 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
274.11 % 20.32 % -84.14 %
(Dec 31 2023)  


DBVT's III. Quarter Q/Q Revenue Comment
Dbv Technologies S a achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 128.57%, to $ 1.60 millions, from $0.70 millions in the second quarter.
DBVT is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Dbv Technologies S A 's Revenue growth quarter on quarter, overall rank is 3349.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #47
Healthcare Sector #462
Overall #3349
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #47
Healthcare Sector #462
Overall #3349
Revenue Q/Q Growth Statistics
High Average Low
274.11 % 20.32 % -84.14 %
(Dec 31 2023)  


DBVT's III. Quarter Q/Q Revenue Comment
Dbv Technologies S a achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 128.57%, to $ 1.60 millions, from $0.70 millions in the second quarter.
DBVT is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Dbv Technologies S A 's Revenue growth quarter on quarter, overall rank is 3349.


Dbv Technologies S A 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 3.84
Y / Y Revenue Growth (TTM) -31.17 %
Year on Year Revenue Growth Overall Ranking # 3701
Seqeuential Revenue Change (TTM) -23.4 %
Seq. Revenue Growth (TTM) Overall Ranking # 1555


Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2026 Dbv Technologies S A reported a drop in Revenue by -31.17% year on year, to $4 millions, compare to the 29.23% growth at Jun 30 2026.

In the Healthcare sector 519 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2980 to 3701.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 32
Healthcare Sector # 520
Overall # 3701

Revenue TTM Y/Y Growth Statistics
High Average Low
480.63 %
 50.98 %
-76.28 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 254
S&P 500 # 1555
Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2026 Dbv Technologies S A reported a drop in Revenue by -31.17% year on year, to $4 millions, compare to the 29.23% growth at Jun 30 2026.

In the Healthcare sector 519 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2980 to 3701.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 32
Healthcare Sector # 520
Overall # 3701

Revenue TTM Y/Y Growth Statistics
High Average Low
480.63 %
50.98 %
-76.28 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 254
S&P 500 # 1555




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DBVT's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Dbv Technologies S A Revenue Growth Rates (DBVT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Dbv Technologies S A (CIK 1613780).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-067930
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Dbv Technologies S A’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.